Maxim Group Gives a Buy Rating to OncoSec Medical

By Jason Carr

In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to OncoSec Medical (NASDAQ: ONCS), with a price target of $5. The company’s shares opened today at $1.89.

McCarthy observed:

“Oncosec announced that the P2b study (PISCES/KEYNOTE-695) in late-stage melanoma evaluating TAVO (DNA-based IL-12, intratumoral) + Keytruda has dosed the first patient.”

According to TipRanks.com, McCarthy is a 1-star analyst with an average return of -0.7% and a 37.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Stellar Biotechnologies, Inc., ImmunoCellular Therapeutics, and Actinium Pharmaceuticals.

OncoSec Medical has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.

The company has a one-year high of $2.95 and a one-year low of $0.88. Currently, OncoSec Medical has an average volume of 2.58M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OncoSec Medical, Inc. engages in the design and commercialize medical products for the treatment of cancer. It involves in the discovery and development of novel immunotherapeutic products to improve treatment options for patients and physicians, which intends to treat oncology indications. The company was founded by Avtar S. Dhillon, Punit S.